GLPwatch
Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.
Am J Gastroenterol · 2025
Last updated 2026-05-28In a study of 120 people with inflammatory bowel disease (IBD) taking GLP-1 drugs, 11.5% reported stomach or gut side effects, which were the most common issue. After one year, blood markers of inflammation (C-reactive protein) dropped, and some people lost weight, especially those taking semaglutide, but hospital stays and gut lining scores did not change.
AI summary of the abstract below.
| Journal | Am J Gastroenterol, 2025 |
|---|---|
| Citations | 20 |
| Relative citation ratio | 8.41 |
| Molecules | — |
Abstract
INTRODUCTION: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.
METHODS: Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.
RESULTS: Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year ( P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.
DISCUSSION: GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.
Verbatim abstract via PubMed 39717004 ↗